TABLE 1.
Groups of tissue/organs matched with disease phenotypes (A) and number of target genes selected as potential candidates for drug repurposing by VarElect aggregate and single group ranks (B).
| (A) Groups of tissue/organs matched with disease phenotypes | |||
| Group # ID | Organ systems | Organs and tissues | Disease phenotypes (symptoms or disease manifestations) |
| Group 1 | Respiratory tract | Lungs, tongue, tonsils, olfactory epithelium | “Fever” OR “cough” OR “pneumonia” OR “dyspnea” OR “pain” OR “hemoptysis” OR “sore throat” OR “chills” OR “inflammation” |
| Group 2 | Digestive system | Stomach, esophagus, colon, duodenum, small intestine and rectum | “Fever” OR “diarrhea” OR “pain” OR “nausea” OR “vomiting” OR “inflammation” |
| Group 3 | Blood cells | n/a | “Fever” OR “chills” OR “inflammation” OR “hemorrhagic” |
| Group 4 | Filtering organs | Spleen, liver, lymph nodes, kidney | “Fever” OR “cough” OR “diarrhea” OR “pain” OR “nausea” OR “vomiting” OR “chills” OR “inflammation” OR “hemorrhagic” |
| Group 5a | Brain areas | Amygdala, Basal Ganglia, Cerebellum, Cerebral Cortex, Hippocampus, Hypothalamus, Midbrain, Olfactory region, Pons and Medulla, Thalamus | “Dizziness” OR “headache” OR “consciousness” OR “encephalopathy” OR “encephalitis” OR “seizures” OR “stroke” OR “delirium” |
| Group 5b | Brain areas | Amygdala, Basal Ganglia, Cerebellum, Cerebral Cortex, Hippocampus, Hypothalamus, Midbrain, Olfactory region, Pons and Medulla, Thalamus | “Ageusia” OR “dysgeusia” OR “hypogeusia” OR “anosmia” OR “hyposmia” OR “myalgia” OR “myelitis” OR “pain” OR “Guillain-Barre” |
| (B) Number of target genes selected as potential candidates for drug repurposing by VarElect aggregate and single group ranks | |||
| Group # ID | Selected gene targets (potential candidates for drug repurposing) | Selected genes | Selection of the first 15 genes |
| Group 1+2+4 (G124) | 101 | See Supplementary Table S11 | See Table 2 |
| Group 1+2+3+4+5 (G12345) | 99 | See Supplementary Table S12 | See Table 3 |
| Group 3 (G3) | 20 | See Supplementary Table S13 | See Table 4 |
| Group 5a (G5a) | 20 | See Supplementary Table S14 | See Table 5 |
| Group 5b (G5b) | 20 | See Supplementary Table S15 | See Table 6 |